Analyses Comparing Visual Acuity Between Ranibizumab and Bevacizumab in the Comparison of Age-Related Macular Degeneration Treatments Trials
- PMID: 25811288
- PMCID: PMC4770887
- DOI: 10.1001/jamaophthalmol.2015.0502
Analyses Comparing Visual Acuity Between Ranibizumab and Bevacizumab in the Comparison of Age-Related Macular Degeneration Treatments Trials
Conflict of interest statement
Comment on
-
Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.Ophthalmology. 2012 Jul;119(7):1388-98. doi: 10.1016/j.ophtha.2012.03.053. Epub 2012 May 1. Ophthalmology. 2012. PMID: 22555112 Free PMC article. Clinical Trial.
-
Sustained visual acuity loss in the comparison of age-related macular degeneration treatments trials.JAMA Ophthalmol. 2014 Aug;132(8):915-21. doi: 10.1001/jamaophthalmol.2014.1019. JAMA Ophthalmol. 2014. PMID: 24875610 Free PMC article. Clinical Trial.
-
Comparative effectiveness of bevacizumab and ranibizumab in the comparison of age-related macular degeneration treatments trials.JAMA Ophthalmol. 2015 Mar;133(3):363-4. doi: 10.1001/jamaophthalmol.2014.4642. JAMA Ophthalmol. 2015. PMID: 25429419 No abstract available.
Similar articles
-
Comparative effectiveness of bevacizumab and ranibizumab in the comparison of age-related macular degeneration treatments trials.JAMA Ophthalmol. 2015 Mar;133(3):363-4. doi: 10.1001/jamaophthalmol.2014.4642. JAMA Ophthalmol. 2015. PMID: 25429419 No abstract available.
-
One-year results of treatment with bevacizumab alone or ranibizumab alone for low visual acuity due to neovascular age-related macular degeneration.J Ocul Pharmacol Ther. 2013 Dec;29(10):865-9. doi: 10.1089/jop.2013.0106. Epub 2013 Sep 20. J Ocul Pharmacol Ther. 2013. PMID: 24053539
-
Sight-saving treatments for age-related macular degeneration. New drugs offer new hope for managing a leading cause of blindness.Johns Hopkins Med Lett Health After 50. 2012 Winter;24(12):1-4. Johns Hopkins Med Lett Health After 50. 2012. PMID: 23757782 No abstract available.
-
Ocular and systemic safety of bevacizumab and ranibizumab in patients with neovascular age-related macular degeneration.Curr Opin Ophthalmol. 2013 May;24(3):205-12. doi: 10.1097/ICU.0b013e32835f8ec0. Curr Opin Ophthalmol. 2013. PMID: 23518613 Review.
-
Ranibizumab for age-related macular degeneration: a meta-analysis of dose effects and comparison with no anti-VEGF treatment and bevacizumab.J Clin Pharm Ther. 2014 Jun;39(3):234-9. doi: 10.1111/jcpt.12146. Epub 2014 Mar 17. J Clin Pharm Ther. 2014. PMID: 24635444 Review.
Cited by
-
Predictive Biomarkers of Age-Related Macular Degeneration Response to Anti-VEGF Treatment.J Pers Med. 2021 Dec 8;11(12):1329. doi: 10.3390/jpm11121329. J Pers Med. 2021. PMID: 34945801 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical